Why One Analyst Thinks Johnson & Johnson Reaches $280

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) has been one of healthcare’s standout performers over the past year, with shares up 48% over the past 12 months and 16% year-to-date. The stock currently trades around $241, well above its 52-week low of $137.67. While most analysts carry more moderate forecasts, with the Street consensus sitting at $238.29, HSBC analyst Morten Herholdt just raised his price target to $280 from $265, maintaining a Buy rating. But can JNJ realistically reach $280 by the end of 2026?

Morten Herholdt’s $280 JNJ Prediction

HSBC argues that the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter. That thesis has real data behind it. The VIX currently sits at 23.51, in the elevated uncertainty range, and is up 14.1% over the past month, reinforcing the case for rotating into defensive sectors. The broader healthcare ETF Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down 2.45% year-to-date, suggesting the sector hasn’t fully re-rated yet and J&J’s individual outperformance stands apart.

Key Drivers of JNJ Stock Performance

1. Oncology franchise compounding: DARZALEX grew 26.6% and CARVYKTI surged 65.8% in Q4 2025, with new Phase 1 bladder cancer data for erda-iDRS showing an 89% complete response rate. A deepening oncology pipeline creates durable, multi-year revenue streams that could support sustained revenue growth.
2. Orthopaedics separation unlocking value: J&J’s planned separation of DePuy Synthes within 18-24 months sharpens focus on higher-growth segments including Oncology, Neuroscience, and Cardiovascular. Leaner business structures historically support multiple expansion, a potential catalyst for multiple expansion.
3. Dividend reliability for retirement income: J&J has raised its dividend for 63 consecutive years, with the quarterly payout now at $1.30 per share. That kind of consistency reflects the company’s long track record of returning capital to shareholders.

What Will It Take for JNJ to Reach $280?

With approximately 2.41 billion shares outstanding, a $280 price target would imply a market capitalization meaningfully above the current $586 billion. Getting there requires three things: continued double-digit oncology growth sustaining revenue momentum toward J&J’s 2026 guidance of approximately $100.5 billion in sales; successful execution on the orthopaedics separation without operational disruption; and macro-driven sector rotation into healthcare as volatility persists.

The primary risk remains STELARA biosimilar erosion, which dragged that product down 47.7% in Q4 2025 and continues to pressure Innovative Medicine growth. Still, with accelerating revenue, a pipeline CEO Joaquin Duato called “the strongest portfolio and pipeline in our history,” and a macro environment that increasingly favors defensive compounders, HSBC’s $280 target reflects a credible, fundamentals-driven basis for the $280 price target.